We report the case of a 55-year-old female who despite having developed extensive chronic graft-versus-host disease (GVHD), relapsed 35 months after a T cellreplete sibling donor bone marrow transplant for Philadelphia-positive chronic myeloid leukaemia (Ph CML). She achieved complete cytogenetic remission after discontinuation of cyclosporin A and administration of two low-dose donor leucocyte infusions (DLI 1 × 10 6 and 5 × 10 6 CD3 + cells/kg). Eighteen months after the first infusion she remains well and in complete cytogenetic remission with a normocellular marrow and no exacerbation of GVHD.
In November 1992, a 53-year-old female with Ph CML in first chronic phase underwent an allogeneic bone marrow transplant from an HLA-compatible female sibling donor. Conditioning consisted of total body irradiation (TBI), 1400cGy in eight fractions, and cyclophosphamide 120 mg/kg. As prophylaxis against the GVHD she received cyclosporin A and short-course methotrexate (8 mg/m 2 on days +2, +4, +8 and +12). She engrafted neutrophils on day +24, but went on to develop grade II skin GVHD, which was treated with intravenous methylprednisolone. She was discharged home on day +46 on a reducing dose of steroids with a blood count as follows: Hb 10.7 g/dl, WBC 3.5 × 10 9 /l, platelets 168 × 10 9 /l. The skin GVHD progressed to extensive chronic GVHD affecting the skin, oral mucosa and vagina. This was treated with prednisolone from 4 months to 31 months post BMT, azathioprine from 7 months to 16 months post BMT and thalidomide from 18 months to 25 months post BMT. The azathioprine and thalidomide were discontinued because of myelosuppresCorrespondence: Dr RE Marcus, Box 234, Dept of Haematology, Addenbrooke's NHS Trust, Hills Rd, Cambridge CB2 2QQ, UK Received 3 September 1997; accepted 13 November 1997 sion and severe neurological side-effects, respectively. Cyclosporin A was discontinued at 9 months post BMT. It was re-started at 24 months after BMT due to failure to control cGVHD with the other agents.
Bone marrow cytogenetics at 7 months post BMT showed 100% Ph negativity and cytogenetics done at 24 months post BMT failed to grow. At 33 months post transplant her blood count was as follows: Hb 12.2 g/dl, WBC 3.2 × 10 9 /l, platelets 271 × 10 9 /l; bone marrow cytogenetics showed 100% Ph negativity. Two months later at routine follow-up the platelet count had risen to 613 × 10 9 /l. A bone marrow examination showed that 40% of the metaphases were Ph+ve, with deletions of 20q− and 7p−. Cyclosporin A was discontinued, but 2 months later (ie 37 months post BMT), the platelet count had risen to 1500 × 10 9 /l, and bone marrow cytogenetics confirmed 100% Ph positivity. She was started on hydroxyurea. In an attempt to induce Ph negativity without exacerbating her GVHD we infused an initial 'test-dose' of 1 × 10 6 CD3+ve donor leucocytes/kg. Two weeks post DLI the platelet count remained elevated at 1700 × 10 9 /l and anagrelide was substituted for the hydroxyurea. Four weeks post first DLI (38 months post BMT), a second DLI of 5 × 10 6 CD3+ve cells/kg was given. One week after this second infusion, the patient became pancytopenic (Hb 10.8 g/dl, WBC 1.5 × 10 9 /l, platelets 48 × 10 9 /l), and a trephine biopsy showed a severely hypoplastic marrow. Cytogenetics revealed 20% Philadelphia negativity. Anagrelide was discontinued after a total of 5 weeks. Four months after the first DLI her blood count was as follows: Hb 13.1 g/dl, WBC 3.4 × 10 9 /l, platelets 177 × 10 9 /l; cytogenetics failed to grow but FISH analysis on interphase cells showed that 9/10 cells were bcr/abl positive. Her trephine biopsy remained hypoplastic. Eight months post first DLI her blood count remained stable (Hb 12.4 g/dl, WBC 3.2 × 10 9 /l, platelets 173 × 10 9 /l); cytogenetics analysis failed and her trephine biopsy showed evidence of recovering hypoplasia. Eighteen months post first DLI she continues to have a normal blood count, cytogenetics now show 100% Ph negativity and her trephine biopsy is normocellular. She remains well with no acute GVHD or exacerbation of her previous cGVHD.
Discussion
Allogeneic bone marrow transplantation is the only known cure for CML. There are two factors which influence the cure rate: firstly, the intensity of the conditioning regimen and secondly the 'graft-versus-leukaemia' phenomenon. There is now substantial evidence for the GVL process including anecdotal reports of allograft patients who relapse re-entering remission after withdrawal of cyclosporin A immunosuppression, and higher relapse rates following syngeneic and T cell-depleted BMT. 1 Since 1990, when Kolb et al 2 reported the first successful use of donor leucocytes to treat three patients with CML who relapsed post sibling-donor allografts, there have been several reports suggesting the therapeutic benefits of this cellular therapy. Kolb et al 3 reported the EBMT data of 84 patients with relapsed CML treated with DLI in 1995. Using a median cell dose of 3 × 10 8 CD3+ve cells/kg, complete remission rates of 78-82% were obtained depending upon whether the relapse was haematological or cytogenetic, respectively. Of 14 patients treated in accelerated phase, however, complete remission was achieved in only one. In univariate analysis, the stage of disease at time of transplantation, the nature of relapse (ie chronic phase or accelerated phase, haematological or cytogenetic) were the strongest influence on response to donor leucocyte infusions. In addition, T cell depletion and the absence of GVHD were favourable pointers to response to DLI. The incidence of grade II GVHD or greater and significant myelosuppression was 41% and 34%, respectively. Patients with CML with evidence of GVHD post DLI, myelosuppression or both had a higher response rate (91%) than those who did not (45%). There is now evidence that the GVL effect can be separated from GVHD, demonstrated in a dose-reponse study published by Mackinnon et al. 4 A series of 22 patients were reported with relapsed CML following T cell-depleted transplants. Nineteen of the 22 achieved remission with DLI, eight of whom required a T cell dose of 1 × 10 7 cells/kg, and of these only one developed GVHD. Eleven patients required higher cell doses (5 × 10 7 to 5 × 10 8 /kg) to achieve remission and eight of these patients developed GVHD. No responses were seen in patients receiving р 1 × 10 6 CD3 + cells/kg. It has recently been shown that higher doses may result in more rapid responses, 5 but not in an increase in the response rate or the incidence of GVHD. Of 30 patients treated at the Hammersmith Hospital, the median time to response was 78 days in those receiving more than the median 1.4 × 10 8 cells/kg, compared to 125 days in those receiving less than the median number of cells.
5
The mechanisms of GVHD and GVL are not fully understood, but several likely GVL effectors have been postulated, including T lymphocytes and natural killer/ lymphokine activated killer cells. 6 The higher response rates seen in patients with CML as compared to acute leukemias may be due to the fact that CML may be more immunogenic, and the more indolent growth pattern of CML lends itself to this type of therapy which requires 2-4 months for a response to occur. 6 Our case shows a number of unusual features: firstly, that the patient relapsed while suffering from severe chronic GVHD, which would normally be protective -it is likely that the extensive immunosuppression required to treat her GVHD influenced the timing of relapse. Secondly, the recurrence of disease did not respond to a reduction in immunosuppression. As she had relapsed in accelerated phase we thought it unlikely that discontinuation of immunosuppression alone would induce remission and hence elected to give her very low dose DLI after stopping immunosuppression. This was associated with transient marrow hypoplasia followed by a recovery of Ph-negative haemopoiesis, suggesting a true cell-mediated differential cytotoxicity towards endogenous haemopoietic progenitors, followed by haemopoietic recovery derived from donor Phnegative progenitors previously quiescent.
In summary, we believe that this is the first report of a patient with extensive chronic GVHD relapsing in accelerated phase after an allogeneic BMT for CML achieving a cytogenetic remission after two very low doses of DL, without exacerbation of GVHD.
